Wikipedia -WSS

Wikipedia

author：explore 2025-09-27 22:49:38 - browse：829

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Allen Institute goes after foundational questions, CEO Costa says

hotspot

WSS

Stories you might have missed in 2023: health, science, medicine

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Medicare Advantage overpayments discussion gets experts fired up

JPM pitch from hospitals? Revenue streams outside of patient care

At JPM 2024, hospital systems pitch financial strength to investors

Achieving telehealth equity for people with hearing loss

focus

Wikipedia

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Some medical students still think black patients feel less pain

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

After affirmative action ruling, medical educators look to 'holistic review'

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

BioMarin wins approval for gene therapy to treat hemophilia A

Congress: Prevent baby formula shortages by passing a new bill

In Memoriam: Notable people who died in 2023

New research sheds light on how often breast cancer is overdiagnosed

focus

Allen Institute goes after foundational questions, CEO Costa says

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Should insurance cover cosmetic surgery?

Arena BioWorks launches in Cambridge to speed drug discovery

Protect nursing home residents from future pandemics

In shift, Texas to cover initial consult for Afghan baby's gene therapy

hotspot

explore

explore

hotspot